OMIC
Singular Genomics Systems, Inc. Common StockOMIC
OMIC
Delisted
OMIC was delisted on the 25th of June, 2024.
Financial journalist opinion
Neutral
GlobeNewsWire
2 months ago
Singular Genomics Announces Closing of Acquisition by Deerfield Management
SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.
Neutral
Accesswire
3 months ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
PRNewsWire
3 months ago
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ: OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Neutral
Accesswire
3 months ago
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
Charts implemented using Lightweight Charts™